⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Revolution Medicines to Participate in November 2026 Investor Conferences
globenewswire.com
RVMD
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
globenewswire.com
RVMD
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
globenewswire.com
RVMD
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
globenewswire.com
RVMD
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
prnewswire.com
EXEL
LLY
RVMD
ONCY
GMAB
Form 8-K
sec.gov
RVMD
RVMDW
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
globenewswire.com
PPCB
RVMD
REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26
prnewswire.com
RVMD
REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26
prnewswire.com
RVMD